MedTrace Logo

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

NCT06921837 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2026-01-27

No results posted yet for this study

Summary

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Conditions

  • Gastric Cancer Adenocarcinoma Metastatic
  • Gastroesophageal Adenocarcinoma

Interventions

DRUG

BDC-4182

Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist

Sponsors & Collaborators

  • Bolt Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Bolt Clinical Development · Bolt Biotherapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-26
Primary Completion
2027-05-31
Completion
2029-05-31
FDA Drug
Yes

Countries

  • Australia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06921837 on ClinicalTrials.gov